Perseus Proteomics Inc.

4882

JP3836800007

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-23 am EDT			5-day change	1st Jan Change
332 ^JPY	+7.10%		+7.10%	-46.28%

Mar. 07	Perseus Proteomics Inc. announced that it has received ¥1.566 million in funding from Barclays Bank PLC (Tokyo Branch)	CI
Feb. 20	Perseus Proteomics Inc. announced that it expects to receive ¥1.566 million in funding	CI

Perseus Proteomics Inc. Provides Earnings Guidance for the Year Ending March 31, 2023

August 12, 2022 at 02:05 am EDT

Perseus Proteomics Inc. provided earnings guidance for the year ending March 31, 2023. For the year, the company expects net sales of JPY 77 million, operating loss of JPY 703 million, loss of JPY 854 million or JPY 72.62 per basic share.

Latest news about Perseus Proteomics Inc.

Perseus Proteomics Inc. announced that it has received ¥1.566 million in funding from Barclays Bank PLC (Tokyo Branch)	Mar. 06	CI
Perseus Proteomics Inc. announced that it expects to receive ¥1.566 million in funding	Feb. 19	CI
Perseus Proteomics Inc. Reports Earnings Results for the Nine Months Ended December 31, 2023	Feb. 14	CI
Perseus Proteomics Inc. Announces on Delay in the End of Phase I Clinical Trial for Polycythemia Vera	Feb. 02	CI
Perseus Proteomics Secures Japanese Patent for Blood Cancer Drug Candidate	Dec. 26	MT
Perseus Proteomics Inc. Reports Earnings Results for the Half Year Ended September 30, 2023	Nov. 13	CI
Perseus Proteomics Successfully Enrolls Patients in Phase I Clinical Trial of Anti-TfR1 Antibody for Polycythemia Vera	23-10-22	MT
Perseus Proteomics Inc. Announces Completion of Patients Enrollment in Phase I Clinical Trial for Polycythemia Vera (PV)	23-10-20	CI
Perseus Proteomics Launches Sales of Three Antibodies	23-10-11	MT
Perseus Proteomics Inc. Announces Sales Launch of New Antibodies/Reagents	23-10-10	CI
Perseus Proteomics, Inc. Announces Provision of Antibody Research Support Service Through Single Cell Cloning Technology	23-09-27	CI
Perseus Proteomics Inc. Announces on Dosing of the First Patient in Phase I/II Clinical Trial for Aggressive NK-Cell Leukemia	23-09-22	CI
Perseus Proteomics, Inc. Announces MOU Agreement on Joint Research on Super-Neutralizing Antibody with University of Toyama and Toyama Prefecture	23-08-29	CI
Perseus Proteomics Inc. Reports Impairment Loss for the First Quarter of the Fiscal Year 2023	23-08-14	CI
Perseus Proteomics Inc. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2024	23-08-14	CI
Perseus Proteomics Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-14	CI
Perseus Proteomics Inc. Announces the Interim Report of Phase I Clinical Trial of PPMX-T003	23-05-28	CI
Perseus Proteomics Inc. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2024	23-05-12	CI
Perseus Proteomics Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-12	CI
Perseus Proteomics Inc. Updates Financial Forecast for the Year 2022	23-04-25	CI
Perseus Proteomics Inc. Announces That PMDA Has Finished Investigation of the Clinical Trial Notification of the Phase I/II Investigator-Led Clinical Trial	23-03-27	CI
Perseus Proteomics Inc. Submits the Clinical Trial Notification of the Phase I/II Investigator-Led Clinical Trial Among Aggressive Nk-Cell Leukemia Patients Using In-Development Anti-Transferrin Receptor Antibody PPMX-T003 as A Therapeutic to the PMDA by Hiroshima University Hospital	23-03-15	CI
An unknown buyer agreed to acquire a 6.38% stake in Perseus Proteomics Inc. from Fujifilm Corporation.	23-03-01	CI
Perseus Proteomics Inc. Reports Earnings Results for the Nine Months Ended December 31, 2022	23-02-13	CI
Perseus Proteomics Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023	23-02-13	CI

Chart Perseus Proteomics Inc.

Duration

Period

More charts

Company Profile

Perseus Proteomics Inc is a Japan-based company principally engaged in the research, development, manufacture and sale of pharmaceuticals. The Company is involved in the research and development of therapeutic drugs for cancer and other diseases and related businesses. The Company is involved in the research, development, licensing, and manufacturing method establishment for commercialization in the fields of drug discovery, antibody research support, as well as antibody and reagent sales. The products include PPMX-T001, a therapeutic agent that targets glypican 3 (GPC3) present on the surface of cancer cell membranes; PPMX-T002, a therapeutic agent that targets cadherin 3 (CDH3) present on the surface of cancer cells; PPMX-T003, a therapeutic agent that targets the transferrin receptor (TfR); PPMX-T004 therapeutic agent targeting cadherin 3 (CDH3) and others.

Sector

Pharmaceuticals

Calendar

2024-05-14 - Q4 2023 Earnings Release

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
PERSEUS PROTEOMICS INC.	-46.28%	23.7M
CSL LIMITED	-2.68%	85.68B
SAMSUNG BIOLOGICS CO.,LTD.	+5.53%	41.4B
BIOGEN INC.	-24.99%	28.22B
UCB	+55.77%	24.64B
BIOMARIN PHARMACEUTICAL INC.	-7.19%	16.98B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-34.20%	13.29B
INCYTE CORPORATION	-17.31%	11.66B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.43%	11.65B
SWEDISH ORPHAN BIOVITRUM AB	-0.60%	8.18B

Biopharmaceuticals